Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on tariffs on the industry. Trump's Department of Commerce is looking into ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Eli Lilly CEO Dave Ricks urged the Trump administration to move fast on ... on tariffs or retaliatory tariffs would have a negative impact on not just Lilly but the entire pharmaceutical industry.

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

One of the more interesting aspects about President Donald Trump's recent tariffs is that ... one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on prescription drug imports.

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Big move on Thursday as investors in Eli Lilly and ... seen whether the Trump administration might institute measures to lower the pricing power of NVO and LLY just when Lilly has the potential ...

Although AbbVie, Eli Lilly ... impact. Michaels noted "penalties in the government channel and with existing contracts in the commercial setting" as barriers to hiking drug prices. However, the ...

President Trump recently warned big drugmakers ... These two policies could have major impacts on AbbVie, Lilly, and Johnson & Johnson. Investors often view Pharmaceutical stocks as safe havens ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...